Introduction
range of 31-33% without rHuEpo treatment from the inception of haemodialysis. The interdialysis weight In the era of recombinant human erythropoietin gain was always up to 5.5-7.5 kg at our institution. (rHuEpo), anaemia can be eÂectively alleviated or Dialysis hypotension frequently occurred and resulted corrected in patients with end-stage renal disease in the shortening of dialysis time (from 4 to 3.0-3.5 h ( ESRD) [1] [2] [3] . The increases in eÂective erythropoiesis per session) and a decrease in blood flow (from 300 to by rHuEpo are dose-dependent over doses ranging 200-250 ml/min) in each event of hypotension. between 15 and 500 U/kg body weight [2, 3] . Although Inadequate dialysis with Kt/V urea [10 ] of 0.8-1.0 was 95% of patients will respond to high doses of rHuEpo, inevitable. individual response is variable with doses ranging from
The haematocrit level and iron status were stationary 40 to 50 U/kg. Though the eÃcacy of rHuEpo treat-during 1 year of follow-up (Figure 1 ). In September ment is impressive, poor responses have been reported 1995 the haematocrit suddenly declined to a level of [4, 5] . Factors known to cause resistance to rHuEpo 27% and rHuEpo treatment was initiated for symptoinclude chronic inflammations, iron deficiency, alumi-matic anaemia. rHuEpo ( EprexA, Cilag, Switzerland ) nium overload, hyperparathyroidism with myelo-was administered subcutaneously twice weekly after fibrosis, occult blood loss, haemolysis, and dialysis. Therapy started with a monthly dose of haemoglobinopathy. The reason for the variation in 8000 U and later increased to 12 000 U. Intravenous response and the mechanism for suppression of the iron therapy (total dose 600 mg) was prescribed using eÂect of rHuEpo remain obscure. Inflammation and a protocol from our previous study [11] due to serum infection represent additional causes of anaemia and ferritin level of 44 mg/l. Briefly, 100 mg of 2% ferric resistance to rHuEpo in patients with chronic renal hydroxide sucrose (Ferrum hausmannA, Switzerland ) failure [6] [7] [8] [9] . We report a case on regular haemodia-was administered intravenously postdialysis twice lysis who developed transitory resistance to rHuEpo weekly. Serum ferritin rose to the level of 296 mg/l 2 treatment with temporal association with uraemic months after iron supplementation. The haematocrit pericarditis.
remained below 27% despite increasing doses of rHuEpo and replenishing the iron reserves. In January 1996, the patient suÂered from chest pain and exerCase report tional dyspnoea. A pericardial friction rub was heard on chest auscultation. Chest X-ray disclosed a sudden A 47-year-old Chinese man presented in 1993 with increase in the size of cardiac silhouette with the waterend-stage renal failure as a consequence of chronic bottle contour compared with the previous films. glomerulonephritis. He started regular haemodialysis Pericarditis with pericardial eÂusion was suspected, thrice weekly at an outpatient haemodialysis facilities and confirmed by echocardiography, which demonin Taipei. Because of frequent attack of dialysis hypo-strated a massive pericardial eÂusion with impending tamponade (Figure 2a ). Five hundred millilitres of Correspondence and oÂprint requests to: Der-Cherng Tarng MD, non-bloody eÂusion was aspirated via echo-guided ferritin to 481 mg/l and a decline in transferrin saturation to 15% ( Figure 1 ). In another aspect the concentration of endogenous serum erythropoietin, measured in duplicate using radioimmunoassay (IncstarA, MN, USA), decreased from baseline of 93 to 54 U/l. We hypothesized that the inflammatory state in uraemic pericarditis was contributing to the patient's poor response to rHuEpo, and immediately began the intensified haemodialysis. In the period 2 February to 1 March 1996, he was treated by non-heparinized haemodialysis 5 times a week for 4-4.5 h/session using a cellulose acetate hollow-fibre changed from FB 130T (NiproA, Nissho, Japan) to CA-170 (CAA, Baxter, USA). During the intensive dialysis, Kt/V urea increased to 1.6-1.7 and the symptoms were dramatically relieved. Treatment protocol then returned to haemodialysis with regional heparinization thrice weekly and continued with a CA-170 dialyser.
The follow-up echocardiography disclosed the resolution of pericardial eÂusion on 1 April, 1996 (Figure 2b ). Plasma CRP and serum ferritin simultaneously reduced to the respective values of 1.1 mg/dl and 51 mg/l. Impressively, the serum erythropoietin level increased to 267 U/l with a concomitant rise in haematocrit level to 33% ( Figure 1 ). The physical performance and quality of life improved significantly. Fig. 1 . Changes in levels of haematocrit, plasma C-reactive protein, rHuEpo treatment was then stopped while the haemserum ferritin, and endogenous serum erythropoietin before, during, atocrit rose to the level of 34-36%. In the 6 months and after the occurrence of uraemic pericarditis.
follow-up after intensive dialysis, plasma CRP, serum ferritin, and transferrin saturation were in the range neutrophils 46%, lymphocytes 48%, and monocytes of 1.0-1.1 mg/dl, 78-95 mg/l, and 38-42% respectively. 6%, and RBC 2070/mm3; protein 6000 mg/dl and sugar The serum erythropoietin concentration gradually 39 mg/dl; no bacterial or mycobacterial growth was returned to baseline level ( 95-97.6 U/l ). seen on eÂusion culture, and no malignant cells on cytological examination.
Discussion
The haematocrit further declined to 23% in spite of a stepwise increase in the rHuEpo doses to 20 000 U monthly. Plasma C-reactive protein (CRP) rapidly Initially our patient did not require rHuEpo treatment to maintain haematocrit level above 30%. Baseline elevated to 15 mg/dl with a parallel rise in serum Uraemic pericarditis and erythropoietin resistance 1053 erythropoietin level was high and acquired cystic dialysis in our patient. His haematocrit paralleled the erythropoietin fluctuations. This relative erythropoietin kidney disease was shown on the sonography. In the absence of other well-established states associated with deficiency, while not the primary mechanism for decreased erythropoiesis, may contribute to the develincreased erythropoietin production and erythropoiesis, it is assumed that acquired cystic kidney disease opment of this form of anaemia.
Before the era of rHuEpo, Silverberg et al. [17 ] is the most likely cause of the phenomenon [12 ] .
In the absence of any obvious cause for blood loss, reported a case who had a sharp decline in the haemoglobin concentration during a prolonged course of haemolysis, or iron deficiency, the sudden drop in haematocrit level and the development of resistance to haemorrhagic pericarditis with recurrent tamponade.
This phenomenon may reflect blood loss into the rHuEpo raised the suspicion of the existence of an unrecognized condition. Patients with acute or chronic pericardial sac and breakdown of red cells. Pericarditis in our case was not haemorrhagic and the relative inflammatory disease frequently exhibit remarkable resistance to the eÂect of rHuEpo. The inflammatory contribution of haemorrhage to rHuEpo resistance is unlikely. Pericarditis may develop in patients being state may be obvious after surgery or tuberculous arthritis [6 ] , or indolent in perinephric abscess [7] , treated with chronic intermittent dialysis and has been attributed to inadequate control of uraemia [18, 19] . vasculitis [8 ] , and occult rejection in a failed graft [9 ] . Unless the physician keeps alert, diagnosis of a subclin-Inadequate dialysis initially was a major problem in our patient. Moreover, inadequate dialysis not only ical inflammation may be diÃcult, and further impeded in the presence of end-stage renal failure. Plasma CRP led to uraemic pericarditis but also was of course another potential reason for a suboptimal response to is a useful marker for confirming and quantitating the severity of inflammation in patients undergoing dialysis rHuEpo therapy [20 ] .
We suggested that echo-guided pericardiocentesis [9, 13 ]. An increase in plasma CRP probably best reflects the inflammatory state of uraemic pericarditis was eÂective for saving life in patients with uraemic pericarditis with circulatory compromise, and useful in our patient. An abrupt onset of resistance to rHuEpo preceded the prevailing symptoms of uraemic pericard-for diagnostic purpose in those without tamponade.
Intensive haemodialysis [18, 19] was successful in resoitis for 3 months. It is typical for this type of rather occult condition. Therefore, when confronted with a lution of pericardial eÂusion in our patient. Increasing the intensity of dialysis and resolution of the inflampatient with unexplained resistance to rHuEpo, it is prudent to determine plasma CRP to rule out the matory condition resulted in a significant increase in the haematocrit. Our report corroborated the findings presence of an underlying inflammation.
The mechanism of inflammation-induced inhibition of Ifudu et al. [20] . The haematocrit regained stable in the range of 34-36% despite cessation of rHuEpo on the eÂect of rHuEpo has remained unclear. Investigators postulated that specific cytokines such as treatment and the clinical condition improved significantly. The advantage and lack of adverse event, from interleukins (IL-1, IL-6), tumour necrosis factor a ( TNFa), and c interferon (cINF ) may play a pivotal a clinical and economical point of view, justify the treatment option. Up to now it is the first report of role in the pathogenesis of the anaemia of chronic inflammations [4, 5, 14] . These inhibitory cytokines not uraemic pericarditis as a cause of resistance to rHuEpo treatment in haemodialysis patients. Inadequate diaonly suppress erythroid progenitor cells but also inhibit reticuloendothelial iron release. Our patient developed lysis may be one cause of poor response to rHuEpo, and additional occurrence of an inflammatory state rHuEpo-resistant anaemia accompanied by an elevation of serum ferritin. Serum iron and percentage of may aggravate this condition. Early detection and prompt management of the underlying disease, if postransferrin saturation were low during the period of uraemic pericarditis despite intravenous iron sible, can restore the responsiveness to rHuEpo and reduce the dose requirements. supplementation. Alvarez-Hernandez et al. [15] proposed that TNF induces hypoferraemia by alteration in the ability of macrophage to handle iron. Rogers et al. [16 ] reported that IL-1 enhances hepatic ferritin References production. Accordingly, we speculated that high levels of inhibitory cytokines may generate ineÂective eryth- 
